MX2021007602A - Derivados de heteroarildihidropirimidina y metodos de tratamiento de infecciones de hepatitis b. - Google Patents
Derivados de heteroarildihidropirimidina y metodos de tratamiento de infecciones de hepatitis b.Info
- Publication number
- MX2021007602A MX2021007602A MX2021007602A MX2021007602A MX2021007602A MX 2021007602 A MX2021007602 A MX 2021007602A MX 2021007602 A MX2021007602 A MX 2021007602A MX 2021007602 A MX2021007602 A MX 2021007602A MX 2021007602 A MX2021007602 A MX 2021007602A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- heteroaryldihydropyrimidine
- infections
- derivatives
- treating hepatitis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En la presente se proporcionan compuestos útiles para el tratamiento de la infección por VHB en un sujeto que lo necesite, composiciones farmacéuticas de estos y métodos para inhibir, suprimir o prevenir la infección por VHB en el sujeto.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2018122258 | 2018-12-20 | ||
US201962791576P | 2019-01-11 | 2019-01-11 | |
PCT/CN2019/126739 WO2020125730A1 (en) | 2018-12-20 | 2019-12-19 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021007602A true MX2021007602A (es) | 2021-08-11 |
Family
ID=71102522
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021007602A MX2021007602A (es) | 2018-12-20 | 2019-12-19 | Derivados de heteroarildihidropirimidina y metodos de tratamiento de infecciones de hepatitis b. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20230165865A1 (es) |
EP (1) | EP3898632A4 (es) |
JP (1) | JP2022513297A (es) |
KR (1) | KR20210106464A (es) |
CN (1) | CN113195499A (es) |
AU (1) | AU2019410640A1 (es) |
BR (1) | BR112021011858A2 (es) |
CA (1) | CA3118764A1 (es) |
IL (1) | IL284116A (es) |
MA (1) | MA54556A (es) |
MX (1) | MX2021007602A (es) |
SG (1) | SG11202105338VA (es) |
TW (1) | TW202035412A (es) |
WO (1) | WO2020125730A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11639350B2 (en) | 2017-06-27 | 2023-05-02 | Janssen Pharmaceutica Nv | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections |
US11053235B2 (en) | 2018-08-09 | 2021-07-06 | Janssen Sciences Ireland Unlimited Company | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases |
EP3898628A4 (en) * | 2018-12-20 | 2022-09-07 | Janssen Pharmaceutica NV | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B VIRUS INFECTIONS |
CN111825676B (zh) * | 2019-04-15 | 2023-10-17 | 广东东阳光药业股份有限公司 | 二氢嘧啶类化合物及其在药物中的应用 |
US20220233526A1 (en) * | 2019-06-18 | 2022-07-28 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators |
WO2020255016A1 (en) * | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators |
WO2022161448A1 (en) | 2021-01-29 | 2022-08-04 | Janssen Sciences Ireland Unlimited Company | Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases |
US20240166649A1 (en) * | 2021-02-09 | 2024-05-23 | Shanghai Visonpharma Co., Ltd. | Dihydropyrimidine compound, preparation method therefor and application thereof |
WO2022257942A1 (en) | 2021-06-09 | 2022-12-15 | Janssen Sciences Ireland Unlimited Company | Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6113285B2 (ja) * | 2012-09-10 | 2017-04-12 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | B型肝炎ウイルス感染症の治療及び予防用の6−アミノ酸ヘテロアリールジヒドロピリミジン |
WO2014184328A1 (en) * | 2013-05-17 | 2014-11-20 | F. Hoffmann-La Roche Ag | 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
KR101933844B1 (ko) * | 2014-03-07 | 2018-12-28 | 에프. 호프만-라 로슈 아게 | B형 간염 바이러스 감염의 치료 및 예방을 위한 6-융합된 헤테로아릴다이하이드로피리미딘 |
AU2015236982B2 (en) * | 2014-03-28 | 2017-12-14 | Sunshine Lake Pharma Co., Ltd. | Dihydropyrimidine compounds and their application in pharmaceuticals |
KR20170113658A (ko) * | 2015-03-16 | 2017-10-12 | 에프. 호프만-라 로슈 아게 | Tlr7 작용제 및 hbv 캡시드 조립 억제제를 사용하는 병용 치료 |
WO2017064156A1 (en) * | 2015-10-16 | 2017-04-20 | F. Hoffmann-La Roche Ag | Novel 6-fused and 2-heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
AR107633A1 (es) * | 2016-02-19 | 2018-05-16 | Hoffmann La Roche | Procedimiento para la preparación del ácido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]-3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxílico |
-
2019
- 2019-12-18 TW TW108146369A patent/TW202035412A/zh unknown
- 2019-12-19 KR KR1020217020628A patent/KR20210106464A/ko not_active Application Discontinuation
- 2019-12-19 CN CN201980084849.2A patent/CN113195499A/zh active Pending
- 2019-12-19 SG SG11202105338VA patent/SG11202105338VA/en unknown
- 2019-12-19 WO PCT/CN2019/126739 patent/WO2020125730A1/en unknown
- 2019-12-19 MA MA054556A patent/MA54556A/fr unknown
- 2019-12-19 JP JP2021534914A patent/JP2022513297A/ja not_active Withdrawn
- 2019-12-19 AU AU2019410640A patent/AU2019410640A1/en not_active Abandoned
- 2019-12-19 BR BR112021011858A patent/BR112021011858A2/pt unknown
- 2019-12-19 CA CA3118764A patent/CA3118764A1/en active Pending
- 2019-12-19 EP EP19897899.1A patent/EP3898632A4/en not_active Withdrawn
- 2019-12-19 US US17/415,712 patent/US20230165865A1/en active Pending
- 2019-12-19 MX MX2021007602A patent/MX2021007602A/es unknown
-
2021
- 2021-06-17 IL IL284116A patent/IL284116A/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL284116A (en) | 2021-08-31 |
AU2019410640A1 (en) | 2021-05-27 |
CN113195499A (zh) | 2021-07-30 |
WO2020125730A1 (en) | 2020-06-25 |
BR112021011858A2 (pt) | 2021-11-30 |
EP3898632A1 (en) | 2021-10-27 |
JP2022513297A (ja) | 2022-02-07 |
EP3898632A4 (en) | 2023-02-22 |
US20230165865A1 (en) | 2023-06-01 |
MA54556A (fr) | 2021-10-27 |
TW202035412A (zh) | 2020-10-01 |
SG11202105338VA (en) | 2021-07-29 |
KR20210106464A (ko) | 2021-08-30 |
CA3118764A1 (en) | 2020-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021007602A (es) | Derivados de heteroarildihidropirimidina y metodos de tratamiento de infecciones de hepatitis b. | |
PH12016501379A1 (en) | Azepane derivatives and methods of treating hepatitis b infections | |
MX2017008720A (es) | Derivados y metodos para tratamiento de las infecciones por hepatitis b. | |
JOP20180008A1 (ar) | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b | |
EA201690979A1 (ru) | Производные азепана и способы лечения инфекций гепатита в | |
MX2018005569A (es) | Vacunas contra el virus de la hepatitis b. | |
EA201792069A1 (ru) | Производные азокана и азонана и способы лечения инфекций гепатита в | |
HK1251219A1 (zh) | 用於治療和預防乙型肝炎病毒感染的新的6,7-二氫吡啶並[2,1-a]酞嗪-2-酮類化合物 | |
MX2017001862A (es) | Nuevas piridazonas y triazinonas para el tratamiento y la profilaxis de infeccion por virus de hepatitis b. | |
PH12018550150A1 (en) | Elimination of hepatitis b virus with antiviral agents | |
MX2016014728A (es) | Dihidroquinolizidinonas novedosas para el tratamiento y profilaxis de la infeccion con virus de la hepatitis b. | |
PH12016501254A1 (en) | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection | |
MX2016009449A (es) | Terapia de combinacion para el tratamiento de infecciones por virus de la hepatitis b (vhb). | |
UA117518C2 (uk) | 6-конденсовані гетероарилдигідропіримідини для лікування та профілактики зараження вірусом гепатиту b | |
MX2018005230A (es) | Terapia de combinacion de un inhibidor del ensamble de la capside del hbv y un interferon. | |
MX2017000312A (es) | Derivados de isoindolina para usarse en el tratamiento de una infeccion viral. | |
BR112017026061A2 (pt) | composto, uso de um composto, e, método de tratamento de uma infecção viral | |
MX2018002707A (es) | Derivados de tetrahidrofurano antivirales. | |
WO2016086153A3 (en) | Use of hsp90 inhibitors for the treatment of hiv infections and aids | |
PH12019500083A1 (en) | Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections | |
PH12016502039A1 (en) | Potent and selective inhibitors of hepatitis c virus | |
MX2019006768A (es) | Peptidos antimicrobianos. | |
MX2018011095A (es) | Compuestos de carbapenem. | |
NZ737820A (en) | Mannose derivatives for treating bacterial infections | |
EP3833387A4 (en) | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF VIRUS INFECTION |